AGENUS INC
No enriched coverage for $AGEN in the last 7 days.
No SEC Form 4 filings for $AGEN in the last 30 days.
See all $AGEN insider activity →Benzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
Agenus' unit has entered a second loan modification agreement with Ocean 1181, according to an SEC filing. The agreement is set to take effect on August 12, 2026.
AGENUS INC (AGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 12, 2026, Agenus West, LLC (the “Borrower”), a subsidiary of Agenus Inc. (the “Company”), and the Company, as guarantor, entered into a Second Loan Modification Agreement (the “Loan Modification Agreement”) with Ocea
Recent AGEN coverage spans corporate actions, market movers and earnings.
Bullish call activity could support AGEN price.
Loan modification terms can change near-term liquidity, covenant headroom, and refinancing risk for Agenus.
The 8-K discloses refinancing terms that extend debt duration and change payment mechanics via stock issuance, affecting dilution and near-term cash needs.
The 8-K is a new, company-specific equity compensation structure that can affect near-term sentiment and option overhang expectations, but it is not a fundamental operating update.
Board expansion and a new director appointment are typically low-to-moderate signal events, with limited direct operational impact.
AlphAI scores every news story that mentions AGEN with an AI model for sentiment and relevance, and aggregates insider trades from AGENUS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Benzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
2 min readAgenus' unit has entered a second loan modification agreement with Ocean 1181, according to an SEC filing. The agreement is set to take effect on August 12, 2026.
1 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 12, 2026, Agenus West, LLC (the “Borrower”), a subsidiary of Agenus Inc. (the “Company”), and the Company, as guarantor, entered into a Second Loan Modification Agreement (the “Loan Modification Agreement”) with Ocea
4 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, the Compensation Committee (the "Committee") of the Board of Directors of Agenus Inc. (the "Company") a
2 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, the board of directors (the “Board”) of Agenus Inc., a Delaware corporation (the “Company”), increased t
2 min readAgenus (AGEN) shares fell about 7% after Q2 results. The company reported Q2 revenue of about $34.5m, while net income swung to a loss of about $0.6m and basic EPS returned to a small loss. Trailing twelve-month profit of $91.8m was driven by a one-off $110.3m gain, raising questions about earnings durability.
5 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer • Previously announced oversubscribed $85 million private placement, with up to $255 million in potential proceeds from milestone-aligned
2 min readBiotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.
7 min readAgenus (Nasdaq: AGEN) said three investigator-sponsored BOT+BAL abstracts were accepted for poster presentation at ESMO 2026 (Oct 23-27) in Madrid. The posters cover neoadjuvant dMMR colorectal cancer (NEOASIS), refractory MSS/pMMR metastatic colorectal cancer, and advanced sarcoma. Agenus did not provide new efficacy figures.
3 min readAgenus Inc. (NASDAQ:AGEN) shares fell Tuesday after a record Monday surge of about 95% to 111% amid profit-taking. On Monday, the company reported Phase 1b data for botensilimab plus balstilimab in refractory MSS metastatic colorectal cancer, with median OS 21.2 months. Agenus also announced an $85M private placement plus up to $255M in warrants to fund its Phase 3 ROBBIN trial and shift from BATTMAN. HC Wainwright raised its AGEN price target to $30.
6 min read
